Regeneron says COVID drug reduces risk of hospitalization, death by 70%

Monday, 17. May 2021 16:34

Regeneron Pharmaceuticals Inc. released on Monday phase 3 trial results for its COVID-19 drug REGEN-COV, stating it reduces the risk of hospitalization or death in non-hospitalized patients by 70% compared to placebo. According to the company, the drug also decreased the symptom duration from 14 to 10 days and resulted in a lower viral load.

The trial was performed with the participation of 4,567 high-risk outpatients with COVID-19. "Despite increasing vaccination rates, many continue to be diagnosed with COVID-19 who could benefit from REGEN-COV due to underlying conditions like asthma or COPD that put them at higher risk for severe disease," said trial investigator Dr. Julie Philley.

Related Links: Regeneron Pharmaceuticals Inc.
Breaking the News / DJ